工程化T细胞力量的另一面：基因改造T细胞作为治疗手段的已观察到的和潜在的毒性
The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy.
作者信息
Bedoya Felipe, Frigault Matthew J, Maus Marcela V
机构信息
Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA.
Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Harvard Medical School, Boston, MA 02115, USA.
出版信息
Mol Ther. 2017 Feb 1;25(2):314-320. doi: 10.1016/j.ymthe.2016.11.011.
Abstract
Autologous T cells modified to recognize novel antigen targets are a novel form of therapy for cancer. We review the various potential forms of observed and hypothetical toxicities associated with genetically modified T cells. Despite the focus on toxicities in this review, re-directed T cells represent a powerful and highly effective form of anti-cancer therapy; we remain optimistic that the common toxicities will become routinely manageable and that some theoretical toxicity will be exceedingly rare, if ever observed.
摘要
经过改造以识别新型抗原靶点的自体T细胞是一种新型癌症治疗方法。我们综述了与基因改造T细胞相关的各种已观察到的和假设的潜在毒性形式。尽管本综述重点关注毒性，但重定向T细胞代表了一种强大且高效的抗癌治疗形式；我们仍然乐观地认为，常见毒性将变得常规可控，并且一些理论上的毒性即使被观察到也将极其罕见。
相似文献
1
The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy.工程化T细胞力量的另一面：基因改造T细胞作为治疗手段的已观察到的和潜在的毒性
Mol Ther. 2017 Feb 1;25(2):314-320. doi: 10.1016/j.ymthe.2016.11.011.
2
Advances in T-cell Immunotherapies.T 细胞免疫疗法的进展。
Hematol Oncol Clin North Am. 2019 Oct;33(5):825-837. doi: 10.1016/j.hoc.2019.05.006. Epub 2019 Jul 4.
3
Adoptive T-cell therapy for cancer: The era of engineered T cells.过继性细胞疗法治疗癌症：工程化 T 细胞的时代。
Eur J Immunol. 2015 Sep;45(9):2457-69. doi: 10.1002/eji.201545552. Epub 2015 Aug 21.
4
CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road.嵌合抗原受体修饰的抗 CD19 T 细胞治疗 B 细胞恶性肿瘤：道路规则。
Expert Opin Biol Ther. 2014 Jan;14(1):37-49. doi: 10.1517/14712598.2014.860442. Epub 2013 Nov 21.
5
Improving the safety of T-Cell therapies using an inducible caspase-9 gene.利用可诱导的半胱天冬酶-9基因提高T细胞疗法的安全性。
Exp Hematol. 2016 Nov;44(11):1013-1019. doi: 10.1016/j.exphem.2016.07.011. Epub 2016 Jul 26.
6
Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.基因修饰 T 细胞免疫疗法：限制副作用带来新挑战。
Gene Ther. 2013 Nov;20(11):1029-32. doi: 10.1038/gt.2013.34. Epub 2013 Jun 27.
7
From CARs to TRUCKs and Beyond: Safely en Route to Adoptive T-cell Therapy for Cancer.从嵌合抗原受体（CAR）到肿瘤浸润淋巴细胞（TIL）及其他：安全踏上癌症过继性T细胞治疗之路
EBioMedicine. 2016 Dec;14:1-2. doi: 10.1016/j.ebiom.2016.11.037.
8
Safety Strategies of Genetically Engineered T Cells in Cancer Immunotherapy.基因工程 T 细胞在癌症免疫治疗中的安全性策略。
Curr Pharm Des. 2018;24(1):78-83. doi: 10.2174/1381612824666171227222624.
9
Strategies to genetically engineer T cells for cancer immunotherapy.用于癌症免疫治疗的T细胞基因工程策略。
Cancer Immunol Immunother. 2016 Jun;65(6):631-49. doi: 10.1007/s00262-016-1842-5. Epub 2016 May 2.
10
Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors.表达嵌合抗原受体的现成免疫细胞的转化意义。
Mol Ther. 2016 Aug;24(7):1178-86. doi: 10.1038/mt.2016.106. Epub 2016 May 16.
引用本文的文献
1
Glioblastoma Therapy: Past, Present and Future.胶质母细胞瘤治疗：过去、现在和未来。
Int J Mol Sci. 2024 Feb 21;25(5):2529. doi: 10.3390/ijms25052529.
2
CrossDome: an interactive R package to predict cross-reactivity risk using immunopeptidomics databases.CrossDome：一个交互式 R 包，用于使用免疫肽组学数据库预测交叉反应性风险。
Front Immunol. 2023 Jun 12;14:1142573. doi: 10.3389/fimmu.2023.1142573. eCollection 2023.
3
Liposomal phytohemagglutinin: In vivo T-cell activator as a novel pan-cancer immunotherapy.脂质体植物血凝素：作为一种新型的泛癌免疫疗法，体内 T 细胞激活剂。
J Cell Mol Med. 2022 Feb;26(3):940-944. doi: 10.1111/jcmm.16885. Epub 2022 Jan 11.
4
Nanoparticle T cell engagers for the treatment of acute myeloid leukemia.用于治疗急性髓系白血病的纳米颗粒T细胞衔接器
Oncotarget. 2021 Sep 14;12(19):1878-1885. doi: 10.18632/oncotarget.28054.
5
Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.工程化 TCR-T 细胞免疫疗法在抗肿瘤精准医学中的利与弊。
Front Immunol. 2021 Mar 30;12:658753. doi: 10.3389/fimmu.2021.658753. eCollection 2021.
6
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide.基于来那度胺调控的可逆转 ON/OFF 开关嵌合抗原受体
Sci Transl Med. 2021 Jan 6;13(575). doi: 10.1126/scitranslmed.abb6295.
7
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.癌症免疫治疗学会（SITC）免疫效应细胞相关不良事件临床实践指南。
J Immunother Cancer. 2020 Dec;8(2). doi: 10.1136/jitc-2020-001511.
8
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.癌症免疫治疗学会关于免疫疗法治疗多发性骨髓瘤的共识声明。
J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000734.
9
Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours.改变肿瘤微环境和逆转肿瘤细胞：治疗恶性肿瘤的新策略。
Cell Prolif. 2020 Aug;53(8):e12865. doi: 10.1111/cpr.12865. Epub 2020 Jun 26.
10
A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity.一个交叉反应性小蛋白结合结构域为研究肿瘤外CAR-T细胞毒性提供了一个模型。
Mol Ther Oncolytics. 2020 Apr 14;17:278-292. doi: 10.1016/j.omto.2020.04.001. eCollection 2020 Jun 26.
本文引用的文献
1
Toxicity and management in CAR T-cell therapy.嵌合抗原受体 T 细胞疗法的毒性与管理。
Mol Ther Oncolytics. 2016 Apr 20;3:16011. doi: 10.1038/mto.2016.11. eCollection 2016.
2
Current tools for predicting cancer-specific T cell immunity.目前用于预测癌症特异性T细胞免疫的工具。
Oncoimmunology. 2016 Apr 25;5(7):e1177691. doi: 10.1080/2162402X.2016.1177691. eCollection 2016 Jul.
3
Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.表达 CD30 嵌合抗原受体的自体 T 细胞治疗复发或难治性霍奇金淋巴瘤的开放性 I 期临床试验。
Clin Cancer Res. 2017 Mar 1;23(5):1156-1166. doi: 10.1158/1078-0432.CCR-16-1365. Epub 2016 Aug 31.
4
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.靶向膜黏蛋白MUC1的癌症相关Tn糖型的工程化嵌合抗原受体T细胞可控制腺癌。
Immunity. 2016 Jun 21;44(6):1444-54. doi: 10.1016/j.immuni.2016.05.014.
5
Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.针对恶性肿瘤相关κ轻链的T淋巴细胞的临床反应。
J Clin Invest. 2016 Jul 1;126(7):2588-96. doi: 10.1172/JCI86000. Epub 2016 Jun 6.
6
Toxicities of chimeric antigen receptor T cells: recognition and management.嵌合抗原受体T细胞的毒性：识别与管理
Blood. 2016 Jun 30;127(26):3321-30. doi: 10.1182/blood-2016-04-703751. Epub 2016 May 20.
7
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.急性淋巴细胞白血病嵌合抗原受体T细胞治疗后细胞因子释放综合征预测生物标志物的鉴定
Cancer Discov. 2016 Jun;6(6):664-79. doi: 10.1158/2159-8290.CD-16-0040. Epub 2016 Apr 13.
8
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.双特异性 T 细胞衔接器（BiTE）抗体构建药物blinatumomab 治疗复发/难治性非霍奇金淋巴瘤患者：I 期研究的最终结果。
J Clin Oncol. 2016 Apr 1;34(10):1104-11. doi: 10.1200/JCO.2014.59.1586. Epub 2016 Feb 16.
9
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.表达抗CD19嵌合抗原受体的同种异体T细胞可诱导异基因造血干细胞移植后进展的B细胞恶性肿瘤缓解，且不引起移植物抗宿主病。
J Clin Oncol. 2016 Apr 1;34(10):1112-21. doi: 10.1200/JCO.2015.64.5929. Epub 2016 Jan 25.
10
Challenges and opportunities of allogeneic donor-derived CAR T cells.同种异体供体来源的嵌合抗原受体T细胞的挑战与机遇。
Curr Opin Hematol. 2015 Nov;22(6):509-515. doi: 10.1097/MOH.0000000000000181.
Zotero 插件